Pancreatic cancer's notorious resistance to targeted therapy may have found its match through an unexpected metabolic vulnerability. When pancreatic tumors develop resistance to KRAS inhibitors—drugs that target mutations present in 95% of these cancers—they hijack cellular energy production in ways that could now be therapeutically exploited.
The resistance mechanism centers on ZBTB11, a transcription factor that becomes overactive when cancer cells evade KRAS inhibition. This protein orchestrates a metabolic shift toward oxidative phosphorylation, essentially rewiring the cell's energy factories to maintain survival despite drug treatment. Researchers developed novel molecular glue degrader compounds that specifically eliminate ZBTB11, forcing resistant cancer cells back into a drug-sensitive state. These degraders demonstrated remarkable precision, targeting the resistant pancreatic cancer cells while leaving normal neurons unharmed—a critical safety consideration given ZBTB11's presence in healthy tissue.
This approach represents a sophisticated evolution in cancer drug development, moving beyond simply blocking protein function to actively destroying problematic proteins. The molecular glue strategy addresses a fundamental challenge in oncology: how to overcome adaptive resistance without creating broader toxicity. For pancreatic cancer, which has among the lowest five-year survival rates of major cancers, this metabolic targeting approach offers genuine promise. The work validates ZBTB11 as a druggable target and provides proof-of-concept that metabolic vulnerabilities in drug-resistant states can be therapeutically exploited. While still in preclinical stages, this research establishes a potentially transformative framework for addressing one of cancer medicine's most persistent obstacles.